Clinical Trial

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-06
Trial Details
NCT Number NCT06868199
Lead Sponsor LaNova Medicines Limited
Conditions Advanced Solid Tumours
Enrollment 87 participants
Start Date 2025-05-06
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-12